{"entity":{"id":"ivospemin","kind":"drug","name":"Ivospemin","aka":[],"tldr":"Ivospemin is an experimental small-molecule drug from Panbela Therapeutics in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.","summary":"Ivospemin (SBP-101) is a small-molecule drug developed by Panbela Therapeutics. The sponsor describes its target as polyamine metabolism, which OnCo does not yet have a target page for. The sponsor states: A small-molecule polyamine metabolic inhibitor administered by subcutaneous injection. ClinicalTrials.gov describes the intervention as: small molecule polyamine metabolic inhibitor for subcutaneous injection. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05254171 (Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer), in pancreatic ductal adenocarcinoma. The largest, NCT05254171, plans to enrol 600 participants with primary completion was scheduled for 2026-08-29 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Ivospemin","url":"https://clinicaltrials.gov/search?intr=Ivospemin"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["panbela-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05254171"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"SBP-101","modality":"small molecule","mechanism":"A small-molecule polyamine metabolic inhibitor administered by subcutaneous injection.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ivospemin/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"panbela-therapeutics","kind":"company","name":"Panbela Therapeutics","route":"/companies/panbela-therapeutics/"}],"trial":[{"id":"nct05254171","kind":"trial","name":"Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer","route":"/trials/nct05254171/"}]}}